# Prostvac in Patients With Biochemically Recurrent Prostate Cancer

> **NCT02649439** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 97 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** PROSTVAC -V
- **BIOLOGICAL:** PROSTVAC-F

## Key facts

- **NCT ID:** NCT02649439
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2019-03-28
- **Final completion:** 2022-10-01
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649439, "Prostvac in Patients With Biochemically Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT02649439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*